Accessibility Statement Skip Navigation
  • Why PRWeb
  • How It Works
  • Who Uses It
  • Pricing
  • Login
  • GDPR
  • Create a Free Account
Return to PRWeb homepage
  • News
  • Resources
  • Contact
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News in Focus
      • Browse News Releases

      • All News Releases
      • Multimedia Gallery

      • All Multimedia
      • All Photos
      • All Videos
  • Business & Money
      • Auto & Transportation

      • Aerospace, Defense
      • Air Freight
      • Airlines & Aviation
      • Automotive
      • Maritime & Shipbuilding
      • Railroads and Intermodal Transportation
      • Supply Chain/Logistics
      • Transportation, Trucking & Railroad
      • Travel
      • Trucking and Road Transportation
      • View All Auto & Transportation

      • Business Technology

      • Blockchain
      • Broadcast Tech
      • Computer & Electronics
      • Computer Hardware
      • Computer Software
      • Data Analytics
      • Electronic Commerce
      • Electronic Components
      • Electronic Design Automation
      • Financial Technology
      • High Tech Security
      • Internet Technology
      • Nanotechnology
      • Networks
      • Peripherals
      • Semiconductors
      • View All Business Technology

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Financial Services & Investing

      • Accounting News & Issues
      • Acquisitions, Mergers and Takeovers
      • Banking & Financial Services
      • Bankruptcy
      • Bond & Stock Ratings
      • Conference Call Announcements
      • Contracts
      • Cryptocurrency
      • Dividends
      • Earnings
      • Earnings Forecasts & Projections
      • Financing Agreements
      • Insurance
      • Investments Opinions
      • Joint Ventures
      • Mutual Funds
      • Private Placement
      • Real Estate
      • Restructuring & Recapitalization
      • Sales Reports
      • Shareholder Activism
      • Shareholder Meetings
      • Stock Offering
      • Stock Split
      • Venture Capital
      • View All Financial Services & Investing

      • General Business

      • Awards
      • Commercial Real Estate
      • Corporate Expansion
      • Earnings
      • Environmental, Social and Governance (ESG)
      • Human Resource & Workforce Management
      • Licensing
      • New Products & Services
      • Obituaries
      • Outsourcing Businesses
      • Overseas Real Estate (non-US)
      • Personnel Announcements
      • Real Estate Transactions
      • Residential Real Estate
      • Small Business Services
      • Socially Responsible Investing
      • Surveys, Polls and Research
      • Trade Show News
      • View All General Business

  • Science & Tech
      • Consumer Technology

      • Artificial Intelligence
      • Blockchain
      • Cloud Computing/Internet of Things
      • Computer Electronics
      • Computer Hardware
      • Computer Software
      • Consumer Electronics
      • Cryptocurrency
      • Data Analytics
      • Electronic Commerce
      • Electronic Gaming
      • Financial Technology
      • Mobile Entertainment
      • Multimedia & Internet
      • Peripherals
      • Social Media
      • STEM (Science, Tech, Engineering, Math)
      • Supply Chain/Logistics
      • Wireless Communications
      • View All Consumer Technology

      • Energy & Natural Resources

      • Alternative Energies
      • Chemical
      • Electrical Utilities
      • Gas
      • General Manufacturing
      • Mining
      • Mining & Metals
      • Oil & Energy
      • Oil and Gas Discoveries
      • Utilities
      • Water Utilities
      • View All Energy & Natural Resources

      • Environ­ment

      • Conservation & Recycling
      • Environmental Issues
      • Environmental Policy
      • Environmental Products & Services
      • Green Technology
      • Natural Disasters
      • View All Environ­ment

      • Heavy Industry & Manufacturing

      • Aerospace & Defense
      • Agriculture
      • Chemical
      • Construction & Building
      • General Manufacturing
      • HVAC (Heating, Ventilation and Air-Conditioning)
      • Machinery
      • Machine Tools, Metalworking and Metallurgy
      • Mining
      • Mining & Metals
      • Paper, Forest Products & Containers
      • Precious Metals
      • Textiles
      • Tobacco
      • View All Heavy Industry & Manufacturing

      • Telecomm­unications

      • Carriers and Services
      • Mobile Entertainment
      • Networks
      • Peripherals
      • Telecommunications Equipment
      • Telecommunications Industry
      • VoIP (Voice over Internet Protocol)
      • Wireless Communications
      • View All Telecomm­unications

  • Lifestyle & Health
      • Consumer Products & Retail

      • Animals & Pets
      • Beers, Wines and Spirits
      • Beverages
      • Bridal Services
      • Cannabis
      • Cosmetics and Personal Care
      • Fashion
      • Food & Beverages
      • Furniture and Furnishings
      • Home Improvement
      • Household, Consumer & Cosmetics
      • Household Products
      • Jewelry
      • Non-Alcoholic Beverages
      • Office Products
      • Organic Food
      • Product Recalls
      • Restaurants
      • Retail
      • Supermarkets
      • Toys
      • View All Consumer Products & Retail

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Health

      • Biometrics
      • Biotechnology
      • Clinical Trials & Medical Discoveries
      • Dentistry
      • FDA Approval
      • Fitness/Wellness
      • Health Care & Hospitals
      • Health Insurance
      • Infection Control
      • International Medical Approval
      • Medical Equipment
      • Medical Pharmaceuticals
      • Mental Health
      • Pharmaceuticals
      • Supplementary Medicine
      • View All Health

      • Sports

      • General Sports
      • Outdoors, Camping & Hiking
      • Sporting Events
      • Sports Equipment & Accessories
      • View All Sports

      • Travel

      • Amusement Parks and Tourist Attractions
      • Gambling & Casinos
      • Hotels and Resorts
      • Leisure & Tourism
      • Outdoors, Camping & Hiking
      • Passenger Aviation
      • Travel Industry
      • View All Travel

  • Policy & Public Interest
      • Policy & Public Interest

      • Advocacy Group Opinion
      • Animal Welfare
      • Congressional & Presidential Campaigns
      • Corporate Social Responsibility
      • Domestic Policy
      • Economic News, Trends, Analysis
      • Education
      • Environmental
      • European Government
      • FDA Approval
      • Federal and State Legislation
      • Federal Executive Branch & Agency
      • Foreign Policy & International Affairs
      • Homeland Security
      • Labor & Union
      • Legal Issues
      • Natural Disasters
      • Not For Profit
      • Patent Law
      • Public Safety
      • Trade Policy
      • U.S. State Policy
      • View All Policy & Public Interest

  • People & Culture
      • People & Culture

      • Aboriginal, First Nations & Native American
      • African American
      • Asian American
      • Children
      • Diversity, Equity & Inclusion
      • Hispanic
      • Lesbian, Gay & Bisexual
      • Men's Interest
      • People with Disabilities
      • Religion
      • Senior Citizens
      • Veterans
      • Women
      • View All People & Culture

  • Hamburger menu
  • Cision PRWeb provides efficient communication tools to continuously engage with target audiences across multiple online channels
  • Create a Free Account
    • ALL CONTACT INFO
    • Contact Us


      11AM ET Sunday – 8PM ET Friday

  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • News in Focus
    • Browse All News
    • Multimedia Gallery
  • Business & Money
    • Auto & Transportation
    • Business Technology
    • Entertain­ment & Media
    • Financial Services & Investing
    • General Business
  • Science & Tech
    • Consumer Technology
    • Energy & Natural Resources
    • Environ­ment
    • Heavy Industry & Manufacturing
    • Telecomm­unications
  • Lifestyle & Health
    • Consumer Products & Retail
    • Entertain­ment & Media
    • Health
    • Sports
    • Travel
  • Policy & Public Interest
  • People & Culture
    • People & Culture
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR

Allterum's development of its 4A10 monoclonal antibody targeting ALL approved to receive support through the National Cancer Institute Experimental Therapeutics Program


News provided by

Fannin

Jan 24, 2024, 15:15 ET

Share this article

Share toX

Share this article

Share toX

Allterum Therapeutics is a Fannin Company
Allterum Therapeutics is a Fannin Company

Allterum Therapeutics, Inc. (Allterum) has been approved to receive support from the National Cancer Institute (NCI) Experimental Therapeutics (NExT) Program. NCI is part of the National Institutes of Health. The approval will support key product development activities for Allterum's 4A10 monoclonal antibody targeting acute lymphoblastic leukemia (ALL). The milestone-driven NExT Program will support a pivotal GLP toxicology study and the initial GMP manufacturing of 4A10, enabling Allterum to submit an Investigational New Drug application and to launch its Phase I clinical trial in 2024.

HOUSTON, Jan. 24, 2024 /PRNewswire-PRWeb/ -- Allterum Therapeutics, Inc. (Allterum) has been approved to receive support from the National Cancer Institute (NCI) Experimental Therapeutics (NExT) Program. NCI is part of the National Institutes of Health. The approval will support key product development activities for Allterum's 4A10 monoclonal antibody targeting acute lymphoblastic leukemia (ALL). The milestone-driven NExT Program will support a pivotal GLP toxicology study and the initial GMP manufacturing of 4A10, enabling Allterum to submit an Investigational New Drug application and to launch its Phase I clinical trial in 2024.

The NExT Program was founded in 2009 to advance promising new drug discovery and development projects and bring cancer therapeutics into the clinic. The NExT Program is not a grant mechanism, rather it provides resources for projects focused on developing therapies for unmet needs in the area of oncology that are not typically addressed by the private sector.

"Acceptance by NExT after a rigorous evaluation process provides further scientific validation for Allterum's 4A10 program, and the NExT Program's support will play a vital role in bringing our novel therapeutic antibody into the clinic to improve outcomes for patients with ALL."

Post this

"We appreciate the support provided by the NExT Program to advance our 4A10 program through our pivotal toxicology study and GMP manufacturing run," said Atul Varadhachary, MD, PhD, President and CEO of Allterum. "Acceptance by NExT after a rigorous evaluation process provides further scientific validation for Allterum's 4A10 program, and the NExT Program's support will play a vital role in bringing our novel therapeutic antibody into the clinic to improve outcomes for patients with ALL."

Leukemias are the most commonly diagnosed pediatric cancer in the U.S., and ALL is the most common leukemia in children. Although current therapies are effective for a majority of patients, the prognosis is poor for patients who have relapsed or are refractory to treatment. Allterum's initial trial will focus on patients who are relapsed or refractory to therapy with follow-up label expansion trials in ALL patients in a first-line setting as well as in patients with other CD127-expressing hematological and solid cancers.

"We have received Orphan Drug Designation and Rare Pediatric Disease Designation for ALL from FDA, which will provide an accelerated path to approval and potentially qualify us for a Pediatric Priority Review Voucher," said Philip Breitfeld, MD, Allterum's Chief Medical Officer. "This funding from NExT will play a vital role in advancing our development program for 4A10. We are eager to progress to Phase I/IIA clinical trials to evaluate our antibody for treating leukemia and potentially other malignancies."

The 4A10 antibody targets CD127 (the interleukin-7 receptor subunit alpha; IL-7R), a protein implicated in driving cancer growth and chemotherapy resistance in ALL and other CD127-expressing cancers. The antibody was invented by NCI senior investigator Scott Durum, PhD and his collaborators, and the technology was licensed to Allterum. Allterum is a spin-out of Fannin, a Houston-based life-science firm developing early-stage therapeutic and medical device technologies.

Early development activities for 4A10, including manufacturing scale-up and preliminary safety studies in non-human primates, were funded by a $2.9M grant from the Cancer Prevention and Research Institute of Texas (CPRIT), matched by a $1.8M Series Seed financing that was led by Fannin. Fannin has also received a $2M NCI SBIR Phase II grant to support the program which, together with Allterum's NExT support and a $12M Product Development Grant from CPRIT, will advance 4A10 to clinical testing in ALL in a trial designed to provide clinical proof-of-concept.

Allterum plans to conduct its ALL Phase I trial in partnership with the Therapeutic Advances in Childhood Leukemia & Lymphoma (TACL) consortium, which includes 31 leading pediatric cancer centers, along with key adult leukemia centers such as The University of Texas MD Anderson Cancer Center. The company expects to initiate clinical testing in 2024.

About Allterum

Allterum Therapeutics, Inc. is a Fannin-founded biopharmaceutical company targeting the IL-7 pathway for the treatment of patients with Acute Lymphoblastic Leukemia (ALL) and other cancers expressing CD127 (IL-7 receptor subunit alpha; IL-7R). The company's lead candidate, 4A10, is a monoclonal antibody targeting CD127 in-licensed from NCI. For more information, visit www.Allterum.com.

About Fannin

Established in 2015, Houston-based Fannin is among the most active early-stage product development groups in the life sciences with a dozen programs/platforms at different stages of development. Fannin advances its pipeline both internally and through Fannin-founded entities with a combination of investor and grant funding. In the last decade, Fannin has brought in ~35 programs, of which a dozen are active including three in the clinic. We have had ~$225 million invested across our programs, $75M from grant funding and $150M from investors. An additional critical element to our model is helping develop life sciences entrepreneurs locally through our talent development programs. Our talent development program, which includes part-time interns and full-time fellows/product development associates, has grown to become one of the largest of its kind. Our over 320 alumni are active in pharma/biotech, medical device/medtech, and VC firms across our ecosystem and nationally. For more information, visit www.FanninInnovation.com, come by the office at 3900 Essex Lane -- Suite 575 in Houston, or email us at [email protected]. 

Media Contact

Serena Miggins, Fannin, 1 713-966-5844, [email protected], www.fannininnovation.com 

SOURCE Fannin

Modal title

Contact PRWeb

  • 11AM ET Sunday – 8PM ET Friday
  • Contact Us

About PRWeb

  • About PRWeb
  • Partners
  • Partnership Programs
  • Editorial Guidelines
  • Resources

Why PRWeb

  • Why PRWeb
  • How It Works
  • Who Uses It
  • Pricing

Accounts

  • Create a Free Account
  • Log in
  • Contact Us

Do not sell or share my personal information:

  • Submit via [email protected] 
  • Call Privacy toll-free: 877-297-8921

Contact Cision

Products

About

My Services
  • All News Releases
  • Online Member Center
  • ProfNet
Cision Distribution Helpline
888-776-0942
  • Legal
  • Site Map
  • RSS
  • Cookie Settings
Copyright © 2025 Cision US Inc.